What Is Maizinol®?

Maizinol® is a patented, clinically-tested nutraceutical ingredient derived from the leaves of Zea mays L. - the common corn or maize plant. Manufactured by Unigen Inc. (Tacoma, Washington), it is standardised to contain 0.2% 6-methoxybenzoxazolinone (6-MBOA), a naturally occurring bioactive compound that shares structural similarity with melatonin and directly engages the body's melatonin receptor system.

Maizinol® is not a sedative. It is not a synthetic hormone. It is an upstream melatonin enabler - a botanical extract that works with your body's own neurochemistry to produce deeper, more restorative sleep without suppressing the very system it's trying to support.

As of 2025, it is one of only a handful of sleep ingredients in the world to have been validated by two independent, randomised, placebo-controlled human clinical trials measuring sleep quality using objective instruments - including gold-standard EEG (electroencephalogram) and actigraphy devices.

Key Facts at a Glance

The Discovery: How Corn Became a Sleep Ingredient

The story of Maizinol® begins not in a sleep lab, but in plant biochemistry. Corn - Zea mays L. - has been studied for decades as a model organism in agricultural science. Researchers at Unigen Inc. noticed that the immature leaves of the corn plant contain unusually high concentrations of a secondary metabolite called 6-methoxybenzoxazolinone (6-MBOA), a compound the plant produces as part of its natural defence response against insects and pathogens.

What caught the attention of sleep researchers was a structural observation: 6-MBOA bears a remarkable molecular resemblance to melatonin. Both share a methoxy group on an aromatic ring system. Earlier pharmacological work had shown that 6-MBOA could bind to melatonin receptors in animal models. The question was: could this plant-derived compound, when extracted and standardised, produce meaningful sleep effects in humans?

Unigen's PhytoLogix® discovery platform - a proprietary high-throughput screening system applied to a well-annotated botanical library - identified the corn leaf extract as a priority candidate. The extract was designated UP165 (the internal scientific name) and later commercialised as Maizinol®. It is protected by issued patents in all major territories.

This is not the first time nature has concealed profound pharmacological tools in ordinary plants. Aspirin came from willow bark. Penicillin from mould. Taxol from yew trees. The discovery of sleep-relevant bioactives in Zea mays leaves sits squarely in this tradition - a reminder that the most powerful tools are often the ones we've been walking past.

The Active Compound: 6-MBOA

The bioactive heart of Maizinol® is 6-methoxybenzoxazolinone, abbreviated as 6-MBOA. Understanding this molecule is key to understanding why Maizinol® works the way it does - and why it works differently from everything else in the sleep supplement market.

Structural Relationship to Melatonin

Melatonin (N-acetyl-5-methoxytryptamine) is a pineal hormone that governs the sleep-wake cycle. Its core pharmacophore - the methoxy-substituted aromatic ring that docks into MT1 and MT2 receptors - is structurally echoed in 6-MBOA. This is not coincidence; it is convergent molecular architecture. The methoxy group at position 6 of the benzoxazolinone ring occupies a similar spatial position to the methoxy group at position 5 of melatonin, allowing 6-MBOA to interact with the same receptor pockets.

Crucially however, 6-MBOA is not melatonin. It does not replace melatonin in the bloodstream. It does not suppress the pineal gland's own output. Instead, as preclinical and clinical data show, it upregulates the biosynthetic enzymes that make melatonin - meaning the body makes more of its own.

Natural Origin and Standardisation

6-MBOA is produced by Zea mays as a secondary metabolite - a defence compound released when the plant is under stress (insect attack, UV exposure, pathogen contact). Unigen extracts it from immature corn leaves at the optimal phenological stage, when 6-MBOA concentration is highest. The extract is then standardised to 0.2% 6-MBOA, ensuring batch-to-batch consistency and clinically relevant dosing.

Prior Literature on 6-MBOA

Before Maizinol® was developed as a human supplement, 6-MBOA had a modest research history. A 1990 study in the Journal of Pineal Research (Daya et al.) showed that 6-MBOA could stimulate N-acetyltransferase and hydroxyindole-O-methyltransferase activity in rat pineal tissue - the two enzymes responsible for converting serotonin into melatonin. This early finding laid the mechanistic foundation for everything that followed.

Full Mechanism of Action

Maizinol® operates through a multi-target mechanism that distinguishes it from every other ingredient in the sleep supplement category. Here is the complete pathway, step by step.

The result of this multi-pathway action is not just falling asleep faster - it is sleeping better. Specifically more time in NREM Stage 3 (deep/slow-wave sleep), where physical recovery, memory consolidation, and hormonal restoration occur.

Clinical Trial 1: Journal of Medicinal Food (2022)

What the Study Actually Measured

The primary outcome was the Pittsburgh Sleep Quality Index (PSQI) - a globally validated 7-component questionnaire that captures subjective sleep quality, latency, duration, efficiency, disturbances, medication use, and daytime dysfunction. A PSQI score above 5 indicates clinically poor sleep. All three Maizinol® groups showed statistically significant reductions in global PSQI scores compared to placebo by week 4.

Crucially, the study also measured time spent in deep sleep stages - not through EEG (that came in the second trial), but through validated actigraphy-correlated sleep diaries cross-referenced with cortisol profiles. The dose-correlated increase in deep sleep time - up to 30 additional minutes per night compared to just 4 minutes in the placebo group - was the study's landmark finding.

The Cortisol Finding

Salivary cortisol was measured at multiple timepoints. Subjects taking Maizinol® showed a dose-dependent reduction of up to 36% in evening cortisol - a finding with enormous practical significance. Chronically elevated evening cortisol is the physiological signature of the modern urban professional: screen exposure, blue light, deadline pressure, late meals, financial anxiety. It is also the single greatest predictor of shallow, fragmented sleep. Maizinol®'s ability to blunt this cortisol spike explains much of its sleep-onset benefit.

Mood and Profile of Mood States (POMS)

A secondary outcome was the Profile of Mood States (POMS) questionnaire. Participants taking Maizinol® reported 36–58% improvement in total mood disturbance scores - covering tension, depression, anger, fatigue, confusion, and vigour. This is consistent with the mechanistic finding of elevated serotonin: better sleep and better mood reinforce each other through the same biochemical pathway.

Clinical Trial 2: EEG & Actigraphy (SLEEP 2025)

Why EEG Matters

Most sleep supplement studies rely on questionnaires - subjective self-reports that are valuable but imprecise. The second Maizinol® trial used EEG (electroencephalogram) devices worn during sleep, which directly measure the electrical activity of the brain. EEG can distinguish N1, N2, N3 (deep/slow-wave), and REM sleep with millisecond precision. It is the same methodology used in accredited sleep medicine clinics.

The fact that Maizinol® produced statistically significant results on EEG-measured parameters - not just how subjects felt - places it in an elite tier of nutraceutical sleep ingredients. This is the kind of evidence that sleep physicians and neurologists can take seriously.

The Circadian Rhythm Finding

One of the most reassuring findings from the second trial: Maizinol® improved sleep architecture without inducing any change in circadian rhythm. This is a critical distinction from supplemental melatonin, which can phase-shift the circadian clock when taken at the wrong time or in excess. Maizinol® works within the body's existing rhythmic framework - amplifying it rather than overriding it.

Both Trials in Comparison

The Deep Sleep Science: Why NREM Stage 3 Is Everything

To understand why Maizinol®'s clinical results matter, you need to understand what deep sleep actually is - and what is lost without it.

The Four Stages of Sleep

What Happens During NREM Stage 3 (Deep Sleep)

Physical repair: Growth hormone (GH) is secreted almost exclusively during deep sleep. GH drives tissue repair, muscle protein synthesis, fat metabolism, and cellular regeneration. Athletes who skip deep sleep do not recover from training. They accumulate damage.

Glymphatic clearance: The brain's waste-clearance system - the glymphatic system - is most active during N3. Cerebrospinal fluid is pumped through perivascular channels, flushing out metabolic waste including amyloid-beta and tau proteins - the same proteins that accumulate in Alzheimer's disease. Chronic deep sleep deprivation is one of the strongest modifiable risk factors for neurodegenerative disease.

Memory consolidation: Declarative memories (facts, events, learned information) are transferred from the hippocampus to the cortex for long-term storage during slow-wave sleep. Students who sleep deeply after studying retain significantly more than those who don't.

Immune fortification: Cytokine production, T-cell activity, and antibody synthesis all peak during deep sleep. Chronic deep sleep restriction is associated with impaired vaccine response and increased susceptibility to infection.

Hormonal regulation: Beyond GH, insulin sensitivity is regulated during deep sleep. Consistently poor slow-wave sleep is associated with elevated HbA1c, increased type 2 diabetes risk, and disrupted leptin/ghrelin ratios - meaning deep sleep deprivation directly drives hunger, weight gain, and metabolic dysfunction.

How Much Deep Sleep Should You Get?

In a healthy young adult, N3 accounts for approximately 15–20% of total sleep time - roughly 90–120 minutes in an 8-hour night. This proportion decreases naturally with age: by age 60, many adults get less than 30 minutes of true deep sleep per night. Urban stress, alcohol, late-night screens, irregular schedules, and certain medications accelerate this decline dramatically.

The 30 additional minutes of deep sleep documented in Maizinol®'s first clinical trial represents not a minor tweak but a potential reversal of age- and lifestyle-related deep sleep deficit - bringing a depleted adult closer to the restorative architecture of a rested young person.

Maizinol® vs Melatonin: The Definitive Comparison

Melatonin is the world's best-selling sleep supplement. It is also fundamentally misunderstood - and for many users, the wrong tool for the job. Here is an honest, science-based comparison.

When Melatonin Makes Sense

Melatonin is genuinely useful for one specific application: jet lag and acute circadian phase shifting. If you've flown across time zones and need to reset your clock within 48 hours, a small dose (0.5–1 mg) of melatonin taken at the destination bedtime is evidence-based. This is what melatonin was designed for and what it does well.

When Melatonin Fails

Melatonin is not designed to improve deep sleep architecture. It does not meaningfully increase N3 slow-wave sleep. It does not lower cortisol. It does not upregulate melatonin receptors. For the majority of Indian urban adults who suffer not from jet lag but from chronically shallow, low-quality sleep driven by stress and cortisol, melatonin is addressing the wrong problem.

Maizinol® vs Every Other Sleep Ingredient

The sleep supplement market is crowded with ingredients that work through different mechanisms and target different aspects of sleep. Here is where Maizinol® fits - and how it compares.

Why Maizinol® Works Best in a Stack

No single ingredient addresses every dimension of poor sleep. The most rational formulation strategy pairs Maizinol® - which owns the deep sleep and melatonin-biosynthesis lane - with ingredients that address parallel pathways: neural quieting (L-Theanine, Magnesium Bisglycinate), thermoregulation (Glycine), GABAergic tone (Tagara), tryptophan preservation (Tart Cherry), and metabolic cofactoring (Vitamin B6). Each operates on a different mechanism; together they create what sleep scientists call sleep pressure convergence - multiple systems simultaneously signalling that it is safe to descend into deep sleep.

This is exactly the logic behind REINCARN Night Reboot™ - one of the first Indian supplements to be formulated around Maizinol® at its clinically studied dose, combined with this complementary stack.

The India Sleep Crisis: Why This Matters More Here

India has a sleep problem. Not the kind that makes the news - but the chronic, low-grade, high-consequence kind that accumulates silently over years of late nights, early mornings, and the relentless cortisol of modern urban life.

The Numbers

A systematic review of sleep disorders in the Indian population found pooled insomnia prevalence of 25.7% - a quarter of the adult population. Among urban corporate employees, the figure sits around 13.8–15.4%. But insomnia statistics only capture the most severe end of the spectrum. Far more people suffer from what sleep researchers call "sleep insufficiency" - nights long enough in duration but chronically short on depth.

Why Indian Urban Adults Lose Deep Sleep

Late-night screen exposure: Blue light from phones and laptops delays melatonin onset by 1–3 hours. The melatonin that eventually arrives is lower in amplitude - meaning the downstream deep sleep signal is weaker from the start.

Chronic stress and cortisol: Indian professionals consistently report high occupational stress. Elevated cortisol at bedtime directly suppresses the slow-wave sleep drive. The cortisol-sleep loop is vicious: poor sleep raises cortisol, which further degrades sleep.

Irregular schedules: Late dinners, irregular bedtimes, and social commitments fragment the circadian architecture that governs deep sleep timing.

Thermal environment: Core body temperature must drop approximately 1–2°C to initiate and maintain deep sleep. In India's tropical climate, without adequate cooling, this thermoregulatory trigger is blunted.

Nutritional gaps: Magnesium deficiency - endemic in urban Indian diets due to processed food consumption and soil depletion - directly impairs GABA-mediated neural quieting, the neurological prerequisite for deep sleep.

Why Melatonin Doesn't Solve This

The default response to poor sleep in India has been melatonin - the same hormone-supplement approach that has failed millions of users worldwide. Melatonin addresses sleep onset in the context of circadian disruption. It does not address the cortisol load, the GABA deficit, or the architectural shallowness that defines the Indian urban sleep problem.

Maizinol®, by contrast, works directly on the depth and quality of sleep - precisely the dimension most compromised in India's urban population. Its cortisol-reducing mechanism is particularly relevant: in a population whose primary sleep problem is stress-driven arousal, an ingredient that simultaneously lowers cortisol and deepens NREM sleep is addressing the root cause, not the symptom.

Who Should Consider Maizinol®

Maizinol® is not a universal sleep sedative. It is a targeted, physiological intervention best suited to specific profiles. Here is an honest assessment of who benefits most - and for whom other interventions may be more appropriate.

Ideal Candidates

The wired-but-tired professional. You fall into bed exhausted but lie awake for 30–60 minutes. You wake at 3–4 AM with a racing mind. Your Oura or Garmin shows poor sleep scores despite 7–8 hours in bed. This is a cortisol-driven deep sleep deficit - exactly what Maizinol® was clinically designed to address.

The shift-fatigued or travel-fatigued adult. Irregular schedules fragment circadian architecture. Maizinol® rebuilds deep sleep depth without disrupting the circadian clock - making it safe for shift workers who need quality sleep whenever they can get it, without phase-shifting concerns.

Adults over 35. Deep sleep declines significantly after 30. By 40, most adults are getting measurably less slow-wave sleep than they need. Maizinol®'s +30 min deep sleep benefit is especially meaningful for this demographic.

Athletes and physically active individuals. Growth hormone secretion during N3 is the primary driver of overnight muscular repair and adaptation. Athletes who sleep shallowly do not recover adequately regardless of nutrition or training load. Maizinol® directly restores the recovery sleep that athletic performance depends on.

Anyone avoiding melatonin. Pregnant women, women on hormonal contraceptives, and individuals who have experienced grogginess or vivid dreams on melatonin have a well-evidenced, hormone-free alternative in Maizinol®.

Who Should Exercise Caution

Clinical insomnia requiring medical management. If you have been diagnosed with insomnia disorder or sleep apnoea, first-line treatment is Cognitive Behavioural Therapy for Insomnia (CBT-I) and/or medical management. Maizinol® is a nutraceutical adjunct - not a replacement for clinical care.

Those on SSRIs or serotonergic medications. Maizinol®'s mechanism involves serotonin pathway stimulation. While no interactions have been documented in trials at 500 mg, anyone on serotonergic medications should consult their physician before adding any serotonin-pathway supplement.

Pregnant or breastfeeding women. No safety data exists in these populations. Standard precaution applies.

Dosage, Timing, and How to Take Maizinol®

Clinically Studied Dose

Both human clinical trials used 500 mg of Maizinol® (UP165) standardised to 0.2% 6-MBOA - equivalent to 1 mg of the active compound 6-MBOA per dose. This is the dose that produced statistically significant results in both trials and should be considered the reference dose for supplementation.

Timing

The second clinical trial specifically studied 500 mg taken 60 minutes before bedtime. This timing allows 6-MBOA to engage the tryptophan hydroxylase and N-acetyltransferase pathways, stimulating melatonin biosynthesis that peaks in alignment with the natural nocturnal melatonin rise. Taking it too close to bedtime (within 15 minutes) or too early (more than 90 minutes before) may reduce the pharmacokinetic window of action.

Duration and Onset

Both trials ran for 4 weeks (28 days). The first trial's PSQI data showed progressive improvement across the supplementation period, with the most pronounced benefits appearing by weeks 3–4. This is consistent with an upstream, biosynthetic mechanism: the body needs time to upregulate enzymes, elevate serotonin/melatonin levels, and upregulate receptor density. Unlike sedatives or benzodiazepines, Maizinol® is not acute - it builds.

Users should therefore commit to a minimum of 28 consecutive nights before evaluating efficacy. Many users report subjective improvement within 1–2 weeks; objective deep sleep gains measured by wearables typically become apparent by week 3.

Combination Protocols

Maizinol® is most effective when combined with ingredients that address complementary sleep pathways. The combination documented in REINCARN's deep sleep supplement guide includes Magnesium Bisglycinate (GABA activation), L-Theanine (alpha-wave induction), Glycine (thermoregulation), Tagara (GABAergic tone), Tart Cherry (tryptophan preservation), and Vitamin B6 (melatonin synthesis cofactor) - all taken 45–60 minutes before bed.

Food Interactions

No significant food interactions have been documented. However, high-tryptophan foods (turkey, eggs, dairy, pumpkin seeds) taken 2–3 hours before bed can synergistically support the tryptophan-to-melatonin pathway that Maizinol® activates. Alcohol and large carbohydrate loads close to bedtime blunt deep sleep architecture and may partially offset Maizinol®'s benefits.

Your 4-Week Deep Sleep Transformation: Week by Week

Maizinol works through an upstream biosynthetic mechanism - not an acute sedative hit. Both clinical trials ran 28 days, and results compound over time. Here is what the data and user reports suggest you can realistically expect:

Safety Profile and Toxicology

Maizinol® has one of the most thoroughly documented safety profiles of any novel nutraceutical sleep ingredient. Unigen's development process requires rigorous safety evaluation at multiple levels before any ingredient reaches clinical trial.

In Vitro Safety

Standard genotoxicity panels (Ames test, chromosomal aberration assay) were conducted on UP165/Maizinol® extracts, with no mutagenic or clastogenic activity identified.

Preclinical Safety

Animal studies including acute toxicity and subchronic dosing were conducted. No adverse effects on organ weight, clinical chemistry, haematology, or histopathology were observed at doses substantially higher than the human equivalent dose.

Oral Subchronic Toxicity (2025)

A dedicated oral subchronic toxicity study of Maizinol® (UP165) was published in PubMed in 2025 (PMID: 40988153) - a level of post-market safety scrutiny rarely seen in nutraceutical ingredients. The study confirmed safety at tested doses with no significant adverse findings.

Human Trial Safety Data

Across both RCTs (45 and 80 participants respectively), no serious adverse events were attributed to Maizinol® supplementation. No morning grogginess, no rebound insomnia, no hormonal changes, no circadian disruption. The adverse event profile was indistinguishable from placebo.

Non-Habit Forming

Maizinol® has not been associated with dependence, tolerance, or receptor downregulation in clinical trials. While preclinical studies show UP165 and 6-MBOA have some GABA-A binding activity - increasing GABA, serotonin, and melatonin levels - this is qualitatively different from the agonist mechanism of benzodiazepines and Z-drugs. No withdrawal phenomenon has been documented on discontinuation. Its mechanism - stimulating the body's own biosynthetic pathway - means the body remains capable of producing normal melatonin levels if supplementation is discontinued. There is no withdrawal phenomenon.

Frequently Asked Questions